

Renal Ultrasound contributes to Fabry Disease Diagnosis

Rodrigo F.C. Azambuja Neves^{1,2}, Patrícia Varela³, Danilo Euclides Fernandes^{1*}, Michelle T. P. Rigueti¹, Simone Geraldini¹, Gustavo Ferreira da Mata¹, Carmen Mendes⁴, Ana Maria Martins⁴, João Bosco Pesquero³, Gianna Mastroianni Kirsztajn¹

¹Section of Glomerulopathies, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil

²Radiology Service of Hospital do Rim, São Paulo, Brazil

³Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil

⁴IGEIM (Innate Errors of Metabolism), Federal University of São Paulo, São Paulo, Brazil

Article Info

Article Notes

Received: August 10, 2020

Accepted: August 25, 2020

*Correspondence:

Dr. Danilo Euclides Fernandes, Section of Glomerulopathies, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil; Telephone No: + 55(11)5576-4848 VOIP 2471; Email: defernandes@unifesp.br

Dr. Gianna Mastroianni Kirsztajn, Section of Glomerulopathies, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil; Telephone No: +55(11)5576-4848 VOIP 2471; Email: gm.kirsztajn@unifesp.br

© 2020 Fernandes DE. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.

Keywords:

Parapelvic cysts
Fabry disease
ultrasound
kidney disease
glomerular filtration rate
glomerulopathy

ABSTRACT

Introduction: Renal impairment in Fabry disease is widely known, but the occurrence of renal cysts as a manifestation of the disease should still be highlighted among radiologists and other physicians.

Objectives: To compare the presence of parapelvic cysts between Fabry disease and other causes of chronic kidney disease (CKD).

Methods: We evaluated demographic, clinical and laboratory data, as well as kidney ultrasound (US) findings in 91 patients with Fabry disease (n=37) and different glomerulopathies (n=54).

Results: Both groups were similar in age ($p = 0.29$), gender ($p = 0.98$), eGFR ($p = 0.10$) and CKD stages ($p = 0.19$). Presence of parapelvic cysts differed significantly between those two groups ($p < 0.0001$ in right and left kidneys; Cohen's $h = 1.15$). When present, diameters of the parapelvic cysts were similar. Both groups had signs of CKD such as corticomedullary undifferentiation. None of the mutations we found in *GLA* gene was associated with a higher prevalence of parapelvic cysts.

Conclusions: When compared to different glomerulopathies, parapelvic cysts were more frequently found in Fabry disease despite age, gender and stage of CKD. Parapelvic cysts on ultrasound can raise suspicion on Fabry disease in patients with kidney disease of unknown etiology especially in the context of a familial nephropathy.

Introduction

Fabry disease (FD) is a rare condition caused by α -Galactosidase A (α -Gal A) deficiency. It is a X-linked disease (OMIM #301500) caused by mutations in the gene that encodes the lysosomal α -Gal A enzyme, which affects glycosphingolipid metabolism. As a result of this deficiency, globotriaosylceramide (Gb3) and other glycosphingolipids accumulate inside the cells, causing organic dysfunction such as kidney damage¹.

Although the major clinical manifestations of FD are well established, it can take years between the onset of the symptoms and final diagnosis, which remains a concern for physicians, patients and their families¹.

Enzymatic analyses screening applies for an initial diagnosis in men who have risk factors or family history of inborn errors of metabolism. Women, who can be heterozygous for such mutations, must be genotyped. In men, genotyping allows family tracing for FD².

Renal impairment in FD is widely known, but the occurrence of

renal cysts as a manifestation of the disease should still be highlighted among radiologists and other specialist physicians. Few reports stated relevance, frequency and morphological characteristics of those renal cysts^{3,4}. Our study shows that kidney ultrasound contributes to Fabry disease diagnosis among other causes of chronic kidney disease (CKD).

Methods

This is a cross-sectional study from the outpatient services of the Federal University of São Paulo (UNIFESP). It was approved by the Ethics Committee of UNIFESP

and written informed consent was obtained from all participants.

We recruited 91 patients with CKD: 37 patients with FD (study group) and 54 patients with glomerulopathies (control group), comparable in age and estimated glomerular filtration rate (eGFR). Inclusion criteria were genetic-proven FD (*GLA* gene mutations as shown in Table A, supplementary material) for study group and biopsy-proven glomerulopathies for control group.

Demographic, clinical and laboratory data were

Table 1. Demographical, clinical and ultrasound characteristics.

	Fabry (n = 37)	Control (n = 54)	p-value
Female, n(%)	19 (51.4)	32 (59.3)	0.29 ^a
Age, years, mean(SD)	36.4 (16.5)	37.7 (14.7)	0.98 ^b
eGFR, mL/min, mean (SD)	97.8 (37.8)	81.0 (40.8)	0.10 ^c
Serum creatinine, mg/dL, mean (SD)	1.2 (1.7)	1.4 (1.2)	0.56 ^b
CKD stages, n(%)			
1	19 (63.3)	27 (51.9)	0.19 ^a
2	4 (13.3)	10 (19.2)	
3	4 (13.3)	5 (9.6)	
4	0 (0.0)	8 (15.4)	
5	1 (3.3)	2 (3.8)	
Cysts	20 (54.1)	13 (24.1)	<0.01 ^a
Unilateral	6 (16.2)	8 (14.8)	1.00 ^a
Bilateral	14 (37.8)	5 (9.3)	<0.001 ^a
Right kidney			
Longitudinal axis, cm, mean (SD)	9.8 (2.2)	10.8 (1.4)	0.01 ^c
Laterolateral, cm, mean (SD)	4.6 (1.1)	4.6 (0.8)	0.84 ^c
Anteroposterior, cm, mean (SD)	7.5 (17.1)	6.0 (7.1)	0.29 ^c
Cysts	18 (48.6)	7 (13.0)	<0.01 ^a
Cortical, n(%)	4 (10.8)	5 (9.3)	1.00 ^a
Largest diameter, cm, mean (SD)	2.5 (2.7)	1.7 (1.2)	0.76 ^b
Smallest, cm, mean (SD)	1.8 (1.8)	1.3 (1.0)	0.31 ^b
Parapelvic, n(%)	11 (29.7)	2 (3.7)	<0.0001 ^a
Largest diameter, cm, mean (SD)	1.0 (0.4)	1.2 (0.0)	0.81 ^b
Smallest, cm, mean (SD)	0.8 (0.2)	0.9 (0.4)	0.81 ^b
Left kidney			
Longitudinal axis, cm, mean (SD)	9.6 (2.5)	10.8 (1.4)	0.08 ^c
Laterolateral, cm, mean (SD)	5.0 (1.2)	5.2 (0.8)	0.33 ^c
Anteroposterior, cm, mean (SD)	4.6 (1.1)	5.0 (0.8)	0.10 ^c
Cysts	23 (62.2)	11 (20.4)	<0.001 ^a
Cortical, n(%)	5 (13.5)	5 (9.3)	0.76 ^a
Largest diameter, cm, mean (SD)	3.2 (3.0)	1.0 (0.4)	0.09 ^b
Smallest, cm, mean (SD)	2.5 (2.7)	0.9 (0.4)	0.12 ^b
Parapelvic, n(%)	17 (45.9)	6 (11.1)	<0.0001 ^a
Largest diameter, cm, mean (SD)	1.1 (0.5)	1.7 (1.2)	0.17 ^b
Smallest, cm, mean (SD)	0.8 (0.2)	1.2 (1.0)	0.10 ^b
CKD US features*, n (%)	5 (13.5)	5 (9.3)	0.6 ^b

^aPearson Chi Square test

^bT-student test

^cMann-Whitney test

*No corticomedullary distinction

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration ratio; n, sample; SD, standard-deviation.




Figure 1. Ultrasound image of parapelvic renal cysts in a patient with Fabry disease.

obtained from the patients' chart. A 17-year specialist in Radiology performed a total abdomen ultrasound using a convex probe. The radiologist was blinded for the patient's diagnosis and determined renal diameters, presence of parapelvic (Figure 1) and/or cortical cysts, and corticomedullary differentiation (increase echogenicity). *GLA* mutations were investigated by Sanger sequencing as described by Varela et al⁵.

Data were typed and organized in Microsoft Excel for Mac®, version 16.35, and analyzed in IBM® SPSS statistics, version 26. We used absolute and relative frequencies (nominal variables) and mean and standard-deviation (numeric variable) to describe our results. We compared the groups through Pearson Chi-Square and Mann-Whitney tests, as appropriate ($\alpha=0.05$, confidence interval=95%). Effect size were calculated according to Cohen's methods.

Results

We analyzed two groups of patients with CKD: 37 with FD and 54 with different glomerular diseases. They were similar in age ($p = 0.24$), gender ($p = 0.79$), eGFR ($p = 0.11$) and CKD stages ($p = 0.06$). In both groups, CKD stage 1 predominated (66.7% of FD group and 51.9% of glomerulopathy group).

Control group accounted for minimal change disease ($n = 3$; 6%), membranous nephropathy ($n = 7$; 13%), lupus nephritis ($n = 14$; 26%), IgA nephropathy ($n = 5$; 9%), pauci immune GN ($n = 2$; 3%), chronic GN ($n = 3$; 6%), focal segmental glomerulosclerosis ($n = 16$; 30%), anti-glomerular basement membrane ($n = 1$; 2%) and Alport syndrome ($n = 3$; 6%).

The control group had slightly larger kidneys than the Fabry group. Presence of renal cysts differed significantly between those two groups in both right ($p < 0.01$) and left ($p < 0.001$) kidneys and parapelvic cysts were responsible for such difference ($p < 0.0001$ in right and left kidneys;

Cohen's $h = 1.15$). When present, diameters of the parapelvic cysts were similar. Both groups had signs of CKD such as corticomedullary undifferentiation. Extrarenal cysts were observed in two patients with FD (one with pancreatic cysts and other with liver cysts), but not in the control group.

FD patients had mutations on all seven exons, and intron 5 (Table A, supplementary material), and none of them was associated with the presence of parapelvic cysts.

Discussion

FD is a rare disease with high morbidity, which clinical picture is well known by physicians dealing with rare diseases, but it is widely underdiagnosed in daily practice. Diversified and unspecific signs and symptoms of the disease explain the difficulties in performing a clinical diagnosis or even raising suspicion of it.

Our results strongly support that renal ultrasound contributes to suspect of FD kidney involvement particularly when family history of kidney diseases are present, due to the higher frequency of parapelvic cysts in patients with FD. Fabry nephropathy is a glomerular disease and this is the reason why we chose a control group of other glomerulopathies. As cystic kidney diseases have unique and well-established findings in ultrasound, they can be easily diagnosed.

In our sample, there were individuals in all stages of CKD, with similar distribution, ensuring that both groups had patients with similar functional renal involvement. Stages 1 and 2 predominated in both groups, and more than half of patients were in stage 1 in both groups, as well. Thus, it was possible to rule out any eventual interference of impairment in GFR (particularly renal failure) on the development of cystic disease in the evaluated groups. It was also relevant that the groups had similar age distribution as it is well established that cortical cysts, for instance, are more frequent in older individuals^{3,4}. The gender distribution was also similar, and this was important as FD has variable clinical pictures related to gender and a more exuberant clinical presentation is usually attributed to males⁷.

Our two groups differed only in terms of frequency of parapelvic cysts. All the other parameters – cortical cysts, renal volume, corticomedullary undifferentiation and lithiasis – seemed not to discriminate between FD and the evaluated glomerulopathies. Some diseases that typically present renal cysts may also show cysts in other organs. As some authors suggested⁶, we performed a complete abdominal ultrasound to identify extrarenal cysts, but they were uncommon in our sample.

Although this is a single-center study with a small sample, which prevent us from generalizing our results,

we have a powerful sample to endorse that parapelvic cysts are more frequent in FD and may flag its diagnosis. Regardless of the expert sonographer in our study, non-expert radiologists who perform ultrasound should be aware of findings that highly suggest a specific condition such as FD⁸⁻¹⁰ because renal ultrasound is commonly performed and plays an important role in the assessment of CKD. Renal ultrasound stands for a non-invasive, cheap and fast imaging method that is widely used in clinical practice. If present, parapelvic cysts could alert for this diagnosis and in the context of familial kidney disease be the earliest indication of FD considering the lack of specificity of most signs and symptoms of such disease.

Conclusion

Our findings endorse that parapelvic cysts on ultrasound can raise suspicion on FD, when compared to other renal diseases. Such cysts are more frequently found in FD despite age, gender and stage of CKD. If radiologists, nephrologists and other physicians are aware of such findings, the earlier diagnosis of FD may contribute to prevent loss of renal function among those patients.

References

1. Waldek, S. & Feriozzi, S. Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy? *BMC Nephrol.* **15**, 72 (2014).
2. Laney, D. A. *et al.* Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. *J. Genet. Couns.* **22**, 555–564 (2013).
3. Pisani, A. *et al.* Parapelvic cysts, a distinguishing feature of renal Fabry disease. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.* **33**, 318–323 (2018).
4. Ries, M. *et al.* Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. *Kidney Int.* **66**, 978–982 (2004).
5. Varela, P. *et al.* Functional Characterization and Pharmacological Evaluation of a Novel **GLA** Missense Mutation Found in a Severely Affected Fabry Disease Family. *Nephron* **144**, 147–155 (2020).
6. Vester, U., Kranz, B. & Hoyer, P. F. The diagnostic value of ultrasound in cystic kidney diseases. *Pediatr. Nephrol.* **25**, 231–240 (2010).
7. Del Pino, M. *et al.* Fabry Nephropathy: An Evidence-Based Narrative Review. *Kidney Blood Press. Res.* **43**, 406–421 (2018).
8. Sayer, J. A., Haslam, P. & Brennan, P. Parapelvic cysts leading to a diagnosis of Fabry disease. *Kidney Int.* **74**, 1366 (2008).
9. Glass, R. B. J. *et al.* Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. *J. Comput. Assist. Tomogr.* **28**, 158–168 (2004).
10. McCloskey, S., Brennan, P. & Sayer, J. A. Variable phenotypic presentations of renal involvement in Fabry disease: a case series. *F1000Research* **7**, 356 (2018).

Supplementary Table:

Table A. GLA gene mutations detected in the patients with Fabry disease submitted to ultrasound evaluation.

n	Age (y)	Gender	Exon/Intron	Protein	Nucleotide	Classification
1	43	M	Exon 1	p.(Trp24fsTer125)	c.59_72dupCCCTCGTTTCCTGG	Classic
2	41	F	Exon 7	p.Arg356Trp	c.1066C>T	Late-onset
3	23	M	Exon 7	p.Arg342Gln	c.1025G>A	Classic
4	59	F	Exon 1	p.Cys63Tyr	c.188G>A	Classic
5	24	M	Exon 1	p.Cys63Tyr	c.188G>A	Classic
6	61	M	Exon 7	p.Arg356Trp	c.1066C>T	Late-onset
7	47	M	Exon 1	p.Cys52Ter	c.156C>A	Classic
8	20	F	Exon 1	p.Cys52Ter	c.156C>A	Classic
9	17	M	Exon 1	p.Cys52Ter	c.156C>A	Classic
10	58	M	Intron 5	IVS5 c.802-2A>G	c.802-2A>G	Classic
11	65	F	Exon 7	p.Arg342Gln	c.1025G>A	Classic
12	40	M	Exon 7	p.Arg356Trp	c.1066C>T	Late-onset
13	62	F	Exon 6	p.Met290Ile	c.870G>A	Late-onset
14	44	F	Exon 1	p.Asn34Asp	c.100A>G	Classic
15	9	M	Exon 1	p.Arg49Pro	c.146G>C	Classic
16	48	F	Exon 1	p.Arg49Pro	c.146G>C	Classic
17	31	F	Exon 1	p.Cys52Phe	c.155G>T	GVUS
18	51	M	Exon 2	p.Arg118Cys	c.352C>T	GVUS
19	27	F	Exons 2 and 6	p.Phe113Leu / p.Asn313Tyr	c.337T>C / c.937G>T	Late-onset / GVUS
20	50	F	Exon 2	p.Phe113Leu	c.337T>C	Late-onset
21	40	M	Exon 7	p.Arg342Gln	c.1025G>A	Classic
22	34	F	Exon 1	p.Cys52Ter	c.156C>A	Classic
23	28	F	Exon 5	p.Arg220Ter	c.658C>T	Classic
24	17	F	Exon 1	p.(Trp24fsTer125)	c.59_72dupCCCTCGTTTCCTGG	Classic
25	53	F	Exon 1	p.(Trp24fsTer125)	c.59_72dupCCCTCGTTTCCTGG	Classic
26	17	F	Exon 1	p.(Trp24fsTer125)	c.59_72dupCCCTCGTTTCCTGG	Classic
27	25	M	Exon 1	p.Asn34Asp	c.100A>G	Classic
28	14	M	Exon 1	p.Asn34Asp	c.100A>G	Classic
29	12	M	Exon 1	p.Asn34Asp	c.100A>G	Classic
30	18	M	Exon 7	p.Arg342Gln	c.1025G>A	Classic
31	46	F	Exon 7	p.Arg342Gln	c.1025G>A	Classic
32	23	M	Exon 7	p.Arg356Trp	c.1066C>T	Late-onset
33	34	F	Exon 7	p.Arg356Trp	c.1066C>T	Late-onset
34	38	F	Intron 5	IVS5 c.802-2A>G	c.802-2A>G	Classic
35	16	F	Exon 7	p.Arg356Trp	c.1066C>T	Late-onset
36	55	M	Exon 3	p.Leu180Phe	c.540G>T	GVUS
37	53	F	Exon 1	p.Cys52Ter	c.156C>A	Classic

Abbreviations: GVUS, genetic variants of unknown significance; M, male; F, female.